The report, released July 30, analyzed pharmacy program participants’ purchase data from April 2023 to March 2024 and provides an estimate of pharmaceutical price changes for 2025.
Vizient’s analysts predicted a 3.70% drug price inflation rate for cardiopulmonary medication in 2025, slightly less than the predicted 3.81% overall drug price inflation rate.
The cardiology medications that saw the biggest share of spending were:
- Trikafta (elexacaftor/tezacaftor/ivacaftor): 0.58%
- Xolair (omalizumab): 0.52%
- Vyndamax (tafamidis): 0.50%
- Nucala (mepolizumab): 0.31%
- Creon, Zenpep (lipase/protease/amylase): 0.28%
- Entresto (sacubitril/valsartan): 0.26%
- Adrenalin (epinephrine): 0.23%
- Repatha (evolocumab): 0.20%
- Fasenra (benralizumab): 0.20%
- Pulmozyme (dornase alfa): 0.18%
The top cardiopulmonary medications with the greatest change in spend were:
- Norepinephrine bitartrate in 0.9% sodium chloride: 348% increase
- Leqvio (inclisiran sodium): 216% increase
- Tezspire (tezepelumab-ekko): 188% increase
- Phenylephrine HCI in .09% sodium chloride: 143% increase
- Vyndamax (tafamidis): 57% increase
- Trikafta (elexacaftor/tezacaftor/ivacaftor): 42% increase
- Repatha (evolocumab): 35% increase
- Entresto (sacubitril/valsartan): 26% increase
- Xolair (omalizumab): 10% increase
Leave a Reply